When government virologist Chris Buck couldn’t get permission to test his experimental vaccine on himself, he founded a nonprofit, brewed beer in his kitchen, and drank it anyway. Five pints daily for five days, followed by two booster rounds. Now he’s on administrative leave, and the scientific establishment is losing its collective mind over what might be either brilliant innovation or dangerous precedent.
The Kitchen Counter Laboratory
Buck engineered baker’s yeast to carry virus particles through fermentation.
Buck discovered four of the 13 known polyomaviruses affecting humans during his 15-year career at the National Cancer Institute. His latest creation? Saccharomyces cerevisiae engineered to produce empty polyomavirus-like particles that survive stomach acid and trigger antibody production in the gut.
The breakthrough came after watching children with BK hemorrhagic cystitis scream so loudly that pediatric hospitals installed soundproofing. These ubiquitous viruses—91% of people are infected by age 9—wreak havoc on transplant patients whose immune systems can’t keep dormant infections in check.
Exploiting the Food Loophole
Regulatory arbitrage turns vaccine development into beverage marketing.
After NIH ethics committees denied his self-experimentation request, Buck established Gusteau Research Corporation (named after the Ratatouille chef) and exploited a regulatory quirk. Foods classified as “generally regarded as safe” face lighter FDA oversight than drugs requiring extensive clinical trials.
His strategy: sell engineered yeast as food first, seek vaccine approval later. The irony cuts deep—Buck can legally brew and distribute “vaccine beer” but cannot legally claim it prevents disease without FDA drug approval.
Scientific Community Divides
Supporters praise innovation while critics warn of eroding vaccine trust.
The backlash arrived swiftly. University of Michigan virologist Michael Imperiale emphasized that “we can’t draw conclusions based on testing this on two people,” particularly for transplant patients requiring rigorous safety data. Medical ethicist Arthur Caplan called the timing disastrous: “This is the worst imaginable time to roll out something that you put on a Substack about how to get vaccinated.”
But Preston Estep, founder of Rapid Deployment Vaccine Collaborative, defended Buck’s approach as selling “vaccine factories, not vaccines,” arguing successful comfort-beverage vaccines could strengthen rather than undermine public trust.
Buck published his preliminary results on his blog “Viruses Must Die” in December 2025, bypassing peer review entirely. Six days after Science News inquired about ethical concerns, Buck received notice of administrative leave pending investigation. The system’s response to his end-run around oversight reveals the central tension: individual moral urgency versus institutional safeguards designed to protect public confidence in vaccines during an era of widespread skepticism.
